MedDataX Logo

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

NCT ID: NCT00675870

Last Updated: 2008-05-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether NRX 195183 is effective in the treatment of relapsed or refractory Acute Promyelocytic Leukemia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A common current therapeutic approach to APL uses oral ATRA and chemotherapy in induction and consolidation. This approach has significantly improved survival in newly diagnosed APL patients. However, approximately 30% of patients relapse. Recently, an approach involving the combination of oral ATRA and arsenic trioxide has been tested. The prognosis for relapsed patients is very poor. This study seeks to investigate NRX 195183 monotherapy in patients who have failed or are resistant to or are intolerant of any prior therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Promyelocytic Leukemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Acute Promyelocytic Leukemia Cancer Leukemia APL ATRA Tretinoid Vesanoid Retinoic Acid Receptor Alpha All Trans Retinoic Acid Arsenic Trioxide Trisenox Retinoid Relapsed or Refractory Acute Promyelocytic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

NRX 195183 Soft Gelatin Capsule

Intervention Type DRUG

Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NRX 195183 Soft Gelatin Capsule

Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of APL morphology or FAB M3 variant confirmed by RT-PCR assay or chromosome analysis/FISH showing t(15:17) translocation. Patients must also have relapse from, resistance to or intolerance of any one or more of the following therapies:

* ATRA
* Cytotoxic chemotherapy
* Arsenic trioxide
* Patients must be 18 or older.
* Bilirubin equal or less than 1.5 times the upper limit of normal.
* Creatinine equal or less than 1.5 times the upper limit of normal.
* Patients entered into this study should be non-pregnant and non-nursing and should not plan on becoming pregnant while on treatment. Treatment under this protocol would expose an unborn child to significant risks. Women and men of reproductive potential should agree to use an effective means of birth control. There is an extremely high risk that a severely deformed infant will result if NRX 195183 is administered during pregnancy.

Exclusion Criteria

* Non-APL, AML patients should be excluded from the study.
* Other serious illnesses which would limit survival to 6 months.
* Psychiatric conditions which would prevent compliance with treatment or informed consent.
* Uncontrolled or severe cardiovascular disease. This would include history of a recent acute myocardial infarction, uncontrolled congestive heart failure, or active angina.
* AIDS or HIV positive patients, although HIV test is not required for accrual.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NuRx Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

NuRx Pharmaceuticals, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sarcoma Oncology Center

Santa Monica, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nonna Snider, BS/BA

Role: CONTACT

Phone: 949-336-7111

Email: [email protected]

Linda Gero

Role: CONTACT

Phone: 949-336-7111

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Victoria Chua

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

195183-202

Identifier Type: -

Identifier Source: org_study_id